Posted by Michael Wonder on 05 Mar 2026
PDUFA action date for Hansa Biopharma's imlifidase BLA set for 19 December 2026
4 March 2026 - If approved, imlifidase will be the first treatment to address highly sensitised patients awaiting kidney transplantation.
Hansa Biopharma today announced that the FDA has notified the company that the previously accepted biologics license application for imlifidase has been assigned a PDUFA action date of 19 December 2026.
